
-
Oil prices dip, stocks mixed tracking Mideast unrest
-
How Paris's Seine river keeps the Louvre cool in summer
-
Welshman Thomas out of Tour of Switzerland as 'precautionary measure'
-
UN says two Iran nuclear sites destroyed in Israel strikes
-
South Africans welcome home Test champions the Proteas
-
Middle Age rents live on in German social housing legacy
-
Israel targets nuclear site as Iran claims hypersonic missile attack
-
China's AliExpress risks fine for breaching EU illegal product rules
-
Liverpool face Bournemouth in Premier League opener, Man Utd host Arsenal
-
Heatstroke alerts issued in Japan as temperatures surge
-
Liverpool to kick off Premier League title defence against Bournemouth
-
Meta offered $100 mn bonuses to poach OpenAI employees: CEO Altman
-
Spain pushes back against mooted 5% NATO spending goal
-
UK inflation dips less than expected in May
-
Oil edges down, stocks mixed but Mideast war fears elevated
-
Energy transition: how coal mines could go solar
-
Australian mushroom murder suspect not on trial for lying: defence
-
New Zealand approves medicinal use of 'magic mushrooms'
-
Suspects in Bali murder all Australian, face death penalty: police
-
Taiwan's entrepreneurs in China feel heat from cross-Strait tensions
-
N. Korea to send army builders, deminers to Russia's Kursk
-
Sergio Ramos gives Inter a scare in Club World Cup stalemate
-
Kneecap rapper in court on terror charge over Hezbollah flag
-
Panthers rout Oilers to capture second NHL Stanley Cup in a row
-
Nearly two centuries on, quiet settles on Afghanistan's British Cemetery
-
Iran says hypersonic missiles fired at Israel as Trump demands 'unconditional surrender'
-
Oil stabilises after surge, stocks drop as Mideast crisis fuels jitters
-
Paul Marshall: Britain's anti-woke media baron
-
Inzaghi defends manner of exit from Inter to Saudi club
-
Made in Vietnam: Hanoi cracks down on fake goods as US tariffs loom
-
Longer exposure, more pollen: climate change worsens allergies
-
Sundowns edge Ulsan in front of empty stands at Club World Cup
-
China downplayed nuclear-capable missile test: classified NZ govt papers
-
Canada needs 'bold ambition' to poach top US researchers
-
US Fed set to hold rates steady as it guards against inflation
-
Sean 'Diddy' Combs trial offers fodder for influencers and YouTubers
-
New rules may not change dirty and deadly ship recycling business
-
US judge orders Trump admin to resume issuing passports for trans Americans
-
Bali flights cancelled after Indonesia volcano eruption
-
India, Canada return ambassadors as Carney, Modi look past spat
-
'What are these wars for?': Arab town in Israel shattered by Iran strike
-
Curfew lifted in LA as Trump battles for control of California troops
-
Chapo's ex-lawyer elected Mexican judge
-
Guardiola says axed Grealish needs to get 'butterflies back in his stomach'
-
Mbappe a doubt for Real's Club World Cup opener
-
Argentine ex-president Kirchner begins six-year term under house arrest
-
G7 minus Trump rallies behind Ukraine as US blocks statement
-
River Plate ease past Urawa to start Club World Cup tilt
-
Levy wants Spurs to be Premier League winners
-
Monahan to step down as PGA Tour commissioner

Pfizer Covid pill preventing hospitalizations and deaths: White House
Pfizer's anti-Covid pill Paxlovid is helping stave off hospitalizations and deaths amid the United States' latest wave of infections, a senior White House official said Wednesday.
Demand for the treatment has soared, with a four-fold increase over the past month and an estimated 20,000 prescriptions being written every day, White House Covid-19 Response Coordinator Ashish Jha told reporters in a press call.
"I think that is actually a really important reason why, despite this very substantial increase in infections, we have not seen a commensurate increase in deaths," he said.
"We have seen hospitalizations rise, but again, not as much as one would have expected at this point, despite the fact that hospitalizations do lag. When you look at ICU care, the rate of ICU hospital admissions is much lower than what one would expect."
President Joe Biden's administration last month embarked on an aggressive push to expand access to the oral antiviral at tens of thousands of locations across the country.
Omicron's subvariants have driven daily new cases to 94,000, a three-fold increase over the last month, with hospitalizations running at 3,000 a day, and deaths at around 275.
Paxlovid, a combination of two drugs, both taken orally over five days, was shown in a clinical trial to reduce hospitalizations and deaths among at-risk people by almost 90 percent.
Concerns have been raised about "Paxlovid rebound" -- in which some patients clear the virus while on the treatment, but test positive after completing their course.
Jha said the government was studying the issue closely, "but I think it is not leading to people getting particularly sick." The rate of rebound during Paxlovid's clinical trial was two percent, but the dominant variant at the time was Delta.
He also encouraged doctors to adopt a "relatively permissive" approach to prescribing the medicine, given the broad eligibility criteria for being high risk.
"You should not get excessively restrictive, we have plenty of supply right now," he advised doctors.
Jha also urged Congress to quickly provide $22.5 billion in Covid funding so that the government could ensure the supply of next generation Covid vaccines, which are expected to protect against multiple variants.
"Other countries are in conversations with the manufacturers and starting to advance their negotiations," he said, warning Americans could be left behind.
If Congress failed to provide funding, "I think it'd be terrible, I think we'd see a lot of unnecessary loss of life if that were to happen," he said, but the Biden administration would try to find a way to provide vaccines to those at highest risk, he added.
X.Habash--SF-PST